I see that the company has not changed the primary trial completion date of 11/2/22. Does that date still seem accomplishable to you guys?

I hope the demand and s/p picks up before trial results release. I have some trading shares I need to unload. Hoping for at least $8-9. Maybe the announcement of new trials will do it.

In this study, was there a difference in the results of the use of pilocarpine and bryostatin?

Less than 100 shares traded in the first 50 minutes. We need some good news.

I would think that with definitely good results, SNPX’s market cap would be much higher than your predictions. I’m see companies in the same space as SNPX, such as AVXL ($700,000,000) with market caps much higher without showing definitely good results.

My bad! Is there a six-figure millions? Lol!

I thought the MC was six-figures before results release last time. It should be the same this time also.

What was the market cap of the company before the last trial results were released?

I totally agree!
Also, I think that it would be fiduciary malfeasance if the company raise money at these low prices while at the same time being secretive about what’s going on in the company, information that could raise the share price.

Coach, you should come up with a few talking points, and we all contact IR and ask him to pass our concerns on to management.

Just voted for MS.
I got distracted reading the article about the connection between AD and apathy on the twitter site.

Cyosol, thanks for the reply.

The top line data will include the primary endpoint, right?
Cytosol, do you have any thoughts on how the company decided to release the data? How do you think the results of the full data will affect the top line data? Am I wrong in thinking releasing the results this way gives us 2 shots on goal?

This is feeling manipulated.

In the last PR the company stated, “ The absence of any drug-related adverse events, as have been observed with the few other therapeutic strategies reaching limited Food and Drug Administration ("FDA") approval for AD, should facilitate our subsequent steps toward clinical utility.”
How do you interpret that statement?

I actually borrowed money to flip at these prices. I think I'll be able to unload them well before results for a profit.

I thought it was 110. Maybe I’m wrong.

I still like our odds.

After the last PR, I now feel as though I can patiently wait until results.
I really like how they are splitting the release of the results into two releases, 26 weeks and 40 weeks results. This gives us two shots on goal. Positive results from either would be seen as an overall success. If the 26 weeks results are positive and the 40 weeks is not, that would be because the drug has to be continuously administered. If the 26 week results are not positive, but the 40 weeks results are positive, that would be because of the delayed affect of the drug. I like it.

In Lane’s article, he provides links to “failed” or “not so good” trial results from Anavex's competitors. Anavex must have some “not so good” trial results or studies also.

Does it seem strange and different, that the last few conferences presentations were PR'ed just a few hours before the event?

It’s not complicated. You evaluate this investment by whether you believe this current trial will be successful or not.

I wonna see 2! :)

With all the patents this company has along with the body of research showing how bryostatin positively affects so many different targets, positive results in the current trial will de-risk the company for BP. They should have to then pay-up for all the potential medical uses within this company's IP.

I totally agree about the future impact of the new synaptic scanning technology.

Do you know of any companies that are further along than SNPX with Synaptogenic MOI?

Thanks Coach, I needed that refresher.

Who the hell is selling down here?

If the company had stayed on the same pace of patient enrollment of the first enrollment announcement, when would’ve complete enrollment been?

I think the delay in enrollment completion is due to the company over enrolling patients to improve the chances of getting a provisional approval if the trial's 10 month efficacy is good.

I'm just hoping there’s no need to raise more money.

Also, I'm guessing that the delay in the announcement of full enrollment is not do to COVID. Hope there’s a pleasant surprise behind it.

I am wondering what will be the cost to SNPX for the two new upcoming trials. Any speculations?

This is a great flip opportunity. The potential downside from this price point is extremely small.

I think this is huge for snpx! We can now see in live humans if bryostatin is growing more synapses. I’m buying more shares.

You would think that the potential of the upcoming trials would prevent this stock from hitting zero if current AD trial doesn’t pan out.

Since this company is targeting a tougher A.D. population, it would seem the market would react more positively to good results from this company than it did for other companies.

You still feel good about SNPX’s chances of winning big?

Could Viagra be the answer? Good for both heads?

https://wgntv.com/news/viagra-reduces-risk-of-developing-alzheimers-disease-by-nearly-70-percent-study-shows/

I know. I was going to put diversify in quotes. I meant diversity with in the neuro-degeneration sector.

Anyone planning on diversifying with some Neuren stock?

Coach, I need your help interpreting these graphs.
I understand the numbers above the bars are the dosages and the numbers inside the bars are the numbers of consecutive weeks injected.
What are the numbers directly under the bars AND the on/off weeks under the bars (if the number of consecutive injections are already given)?